Open AccessProgrammed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study
Author(s) -
Nehad M. Ayoub,
Mohammad M. Fares,
Raya Marji,
Samir M Al Bashir,
Rami J. Yaghan
Publication year - 2021
Publication title -
breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.19
H-Index - 27
ISSN - 1179-1314
DOI - 10.2147/bctt.s333123
Subject(s) - medicine , breast cancer , oncology , immune checkpoint , cancer , interquartile range , lymphovascular invasion , surgical oncology , immunohistochemistry , pd l1 , immunotherapy , metastasis
Tumor expression of programmed death-ligand 1 (PD-L1) is associated with evasion of immune response in several types of malignancies and such expression may render patients eligible for PD-L1 inhibitors. The use of immune checkpoint blockade therapy has been recently approved for the treatment of breast cancer. However, PD-L1 expression data are lacking among Jordanian breast cancer patients. In this study, the tumor PD-L1 expression was characterized in breast cancer patients to assess their eligibility for immune checkpoint blockade therapy. The study also aimed to explore the association between tumoral PD-L1 expression and the clinicopathologic characteristics and the prognostic factors in patients with breast cancer.